Atossa Therapeutics
ATOS
Atossa Therapeutics (ATOS) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.05
- EPS estimate
- −$0.86
- EPS surprise
- −21.74%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.86 | −$1.05 | −21.74% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.85 | −$0.75 | +11.76% | $0.00 | SEC |
| Q4 2024 | Mar 25, 2025 | −$0.95 | −$0.60 | +36.84% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.90 | −$0.90 | +0.00% | $0.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.90 | −$0.75 | +16.67% | $0.00 | SEC |
| Q1 2024 | May 13, 2024 | −$1.00 | −$0.75 | +25.00% | $0.00 | SEC |
| Q4 2023 | Apr 1, 2024 | −$0.90 | −$0.90 | +0.00% | $0.00 | SEC |
| Q3 2023 | Nov 13, 2023 | −$1.00 | −$0.75 | +25.00% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.90 | −$1.20 | −33.33% | $0.00 | SEC |
| Q1 2023 | May 15, 2023 | −$0.90 | −$0.75 | +16.67% | $0.00 | SEC |
| Q4 2022 | Mar 22, 2023 | −$0.98 | −$0.90 | +7.69% | $0.00 | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.83 | −$0.90 | −9.09% | $0.00 | — |
| Q2 2022 | Aug 8, 2022 | −$0.75 | −$0.75 | +0.00% | $0.00 | — |
| Q1 2022 | May 9, 2022 | −$0.75 | −$0.60 | +20.00% | $0.00 | — |
| Q4 2021 | Feb 28, 2022 | −$0.68 | −$0.60 | +11.11% | $0.00 | — |
| Q3 2021 | Nov 15, 2021 | −$0.83 | −$0.60 | +27.27% | $0.00 | — |
| Q2 2021 | Aug 13, 2021 | −$0.53 | −$0.90 | −71.43% | $0.00 | — |
| Q1 2021 | May 14, 2021 | −$0.75 | −$0.60 | +20.00% | $0.00 | — |
| Q4 2020 | Mar 31, 2021 | −$3.75 | −$13.20 | −252.00% | $0.00 | — |
| Q3 2020 | Nov 13, 2020 | −$5.18 | −$5.10 | +1.45% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Atossa Therapeutics (ATOS) last report earnings?
Atossa Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did ATOS beat earnings estimates?
No. Atossa Therapeutics reported EPS of −$1.05 for Q2 2025 against a −$0.86 estimate — a 21.74% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.